ClinicalTrials.gg
TerminatedNCT05849129AIVAAUpdated Oct 14, 2026

Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer

A Phase 2 interventional study of Ascorbic acid and Normal Saline in Lung Cancer, sponsored by The Canadian College of Naturopathic Medicine. Terminated at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by The Canadian College of Naturopathic Medicine · Phase 2, Interventional, and Supportive care

How we know

Why this study was terminated
Insufficient recruitment
Updated Oct 14, 2026Now TerminatedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
3
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 383 studies in Lung Neoplasms with a site in Canada — 66 open to participants now, 99 under way, 26 of them phase 3. Lung Neoplasms · Canada.

Enrollment
306th of 315
3 · median 100
Started
2024
with 11 others
Phase 2
77 of 383
8 open now
Registered
332nd of 383
by date

Among the 383 studies in Lung Neoplasms with a site in Canada, this one is the 306th largest by enrollment of the 315 interventional ones that give a count, is one of 12 that started in 2024, is one of 77 in phase 2, and was the 332nd registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

66 of the 383 studies in Lung Neoplasms with a site in Canada are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 383 studies in Lung Neoplasms with a site in Canada, or all of them as a file.
02

Study summary

This is a two arm RCT evaluating the effect of intravenous vitamin C versus placebo in patients with incurable non-small cell lung cancer. Participants in both arms will be receiving platinum doublet chemotherapy with or without concurrent immunotherapy as standard care. We plan to enroll 90 patients over 5 years.

03

Conditions studied

  • Lung Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults (≥18 years of age) seen at TOHCC with stage IIIB or IV primary non-small cell lung cancer
  2. Eligible and scheduled for platinum-doublet chemotherapy with or without concurrent immunotherapy

Exclusion criteria

Exclusion Criteria:

  1. status greater than 2
  2. Previously received IVC within 6 months prior to randomization
  3. Biochemical deficiency in G6PD
  4. Estimated (eGFR) less than 45 mL/min
  5. Currently taking insulin or warfarin
  6. History of severe renal dysfunction or hemochromatosis
  7. Previously undergone cytotoxic chemotherapy or immunotherapy within 12 months prior to randomization
  8. If pregnant or planning to become pregnant: not a carrier of the gene for G6PD deficiency
  9. Currently taking an product or participation in an investigational study within the past 30 days
  10. Any reason which, under the discretion of the Principal Investigator or delegate, would preclude the patient from participating
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Intravenous Vitamin C

    1g/kg IVC administered twice weekly for 6 months.

    Drug: Ascorbic acid

  • Placebo comparator
    Normal Saline

    Equivalent volume normal saline administered twice weekly for 6 months.

    Other: Normal Saline

Interventions

  • High dose ascorbic acid delivered intravenously

    Also known as: Vitamin C

  • OtherNormal Saline

    0.9% NaCl solution

    Also known as: Sodium Chloride Solution

06

What researchers measure

Primary outcomes

  1. Change in Quality of Life

    Participant reported quality of life (QOL) measured using the Functional Assessment of Cancer Therapy - Lung (FACT-L). FACT-L is a validated tool for assessing QOL in patients with lung cancer. FACT scores are normalized to values between 0-100, where 0 is the worst QOL and 100 is the best QOL imaginable. Each chemotherapy cycle is 3 weeks in length.

    Time frame: Baseline, Chemo cycles 1-4, 6 months, 12 months

Secondary outcomes

  1. Chemotherapy-Related Toxicities

    Frequency of adverse events (AE) which are commonly experienced by patients undergoing chemotherapy. Measured using the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). 31 symptoms were selected by the investigators.

    Time frame: 12 months

  2. Frequency of Discontinuation of Chemotherapy

    Patients often discontinue chemotherapy due to side effects. The investigators will monitor the incidence of stopping chemotherapy and compare the number of patients who stop chemotherapy in both arms.

    Time frame: 6 months

  3. Change in General Symptom Burden

    Measured using the Edmonton Symptom Assessment Scale, which measures 9 symptoms commonly experienced by cancer patients. Each symptom is rated on a scale of 0-10, where 0 is the best symptom and 10 is the worst symptom. Each chemotherapy cycle is 3 weeks in length.

    Time frame: Baseline, chemo cycles 1-4, 6 months, 12 months

  4. Change in C-Reactive Protein Levels

    The investigators will monitor the changes in C-reactive protein (CRP), a common indicator of systemic inflammation. Mean changes in CRP will be compared between arms. Each chemotherapy cycle is 3 weeks in length.

    Time frame: Baseline, chemo cycles 1-4, 6 months, 12 months

  5. Tumour Progression

    The investigators will monitor tumour progression using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, which measures the incidence of complete response, partial response, stable disease, and progressive disease during treatments.

    Time frame: 12 months

  6. Survival

    The incidence of all cause mortality will be compared between arms.

    Time frame: 24 months

  7. Safety

    The investigators will monitor the incidence of all adverse events in both arms to add to the safety profile of IVC in this population.

    Time frame: 6 months

  8. Cytotoxicity

    The investigators will assess the ability of IVC to bring serum ascorbate levels to at least 15mM, which is the hypothesized level at which cytotoxic effects may occur. Levels 15mM or above will be considered adequate.

    Time frame: 12 months

07

Study locations

1 site
  • The Ottawa Hospital
    Ottawa, Ontario K1H8L6, Canada
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual participant data will not be shared with other researchers. Cumulative data not present in the manuscript or on this website may be shared upon request.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Oct 2024 to primary completion in Sep 2026, 23 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Oct 2030 → Sep 2026 and completion Oct 2031 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2023
First posted
May 8, 2023
StartActual
Oct 1, 2024
Primary completionActual
Sep 24, 2026was Oct 2030
CompletionActual
Sep 24, 2026was Oct 2031
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated Insufficient recruitment
changed Oct 14, 2026
Primary completion
Oct 1, 2030→Sep 24, 2026 (actual)
Oct 14, 2026
Study completion
Oct 1, 2031→Sep 24, 2026 (actual)
Oct 14, 2026
Enrollment
90 (estimated)→3 (actual)
Oct 14, 2026
Documents
Show all 1 update
  1. Oct 14, 2026
    Recruiting→Terminated
    Why stopped Insufficient recruitment
    Primary completion Oct 1, 2030→Sep 24, 2026 (now actual)
    Study completion Oct 1, 2031→Sep 24, 2026 (now actual)
    Enrollment 90 (estimated)→3 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05849129
Lead sponsor
The Canadian College of Naturopathic Medicine
Responsible party
Sponsor
First posted
May 8, 2023
Start date
Oct 1, 2024
Primary completion
Sep 24, 2026
Completion
Sep 24, 2026
Last update
Oct 14, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ascorbic Acid

Start the discussion